31st Jan 2023 8:30 am |
RNS |
Notice of Results |
23rd Jan 2023 8:00 am |
RNS |
License to Takeda for Fruquintinib outside China |
18th Jan 2023 2:30 pm |
RNS |
Inclusion of ORPATHYS in NRDL in China |
3rd Jan 2023 8:30 am |
RNS |
Enrollment Completed in Phase 3 Trial |
30th Dec 2022 8:30 am |
RNS |
Blocklisting Six Monthly Return |
19th Dec 2022 10:00 am |
RNS |
FDA NDA Rolling Submission for Fruquintinib |
15th Nov 2022 7:00 am |
RNS |
HUTCHMED Announces Strategy Update |
14th Nov 2022 7:00 am |
RNS |
Positive Topline Phase 3 Result in Fruquintinib |
27th Oct 2022 12:30 pm |
RNS |
HUTCHMED Initiates Phase 2/3 Trial of Fruquintinib |
21st Oct 2022 9:30 am |
RNS |
Vesting of awards under the LTIP |
10th Oct 2022 9:30 am |
RNS |
Phase II/III Trial of Sovleplenib for in China |
30th Sep 2022 9:30 am |
RNS |
Total Voting Rights |
14th Sep 2022 11:00 am |
RNS |
Share Option Scheme and Long Term Incentive Plan |
8th Sep 2022 7:00 am |
RNS |
FRESCO-2 Colorectal Cancer MRCT Data Highlights |
23rd Aug 2022 10:00 am |
RNS |
Holding(s) in Company |
23rd Aug 2022 9:30 am |
RNS |
HUTCHMED To Present FRESCO-2 Data at ESMO 2022 |
9th Aug 2022 9:30 am |
RNS |
First Participant in Phase I Trial of IMG-004 |
8th Aug 2022 9:30 am |
RNS |
Preliminary results from SAVANNAH Phase 2 Trial |
8th Aug 2022 7:00 am |
RNS |
FRESCO-2 Study Has Met Primary Endpoint |
1st Aug 2022 12:04 pm |
RNS |
Interim Results and Business Updates |
1st Aug 2022 7:00 am |
RNS |
HUTCHMED Initiates Bridging Study of Tazemetostat |
15th Jul 2022 9:30 am |
RNS |
HUTCHMED Initiates Phase I Trial of HMPL-A83 |
13th Jul 2022 7:00 am |
RNS |
Results of SAVANNAH Global Phase II Trial at WCLC |
6th Jul 2022 7:00 am |
RNS |
First Participants in Phase I Trial of IMG-007 |
30th Jun 2022 9:30 am |
RNS |
Total Voting Rights |
29th Jun 2022 9:30 am |
RNS |
Blocklisting Six Monthly Return |
27th Jun 2022 9:30 am |
RNS |
HUTCHMED to Announce 2022 Half-Year Results |
1st Jun 2022 9:30 am |
RNS |
TAZVERIK® Approved in Hainan Pilot Zone |
24th May 2022 11:00 am |
RNS |
LTIP and Share Options |
16th May 2022 12:00 pm |
RNS |
Appointment of Non–Executive Director |
3rd May 2022 7:00 am |
RNS |
HUTCHMED Receives CRL from the US FDA |
27th Apr 2022 2:30 pm |
RNS |
Annual General Meeting Poll Results |
21st Apr 2022 9:30 am |
RNS |
Vesting of awards under Long Term Incentive Plan |
31st Mar 2022 7:00 am |
RNS |
Update on Status under HFCAA |
23rd Mar 2022 8:30 am |
RNS |
2021 Annual Report and Notice of AGM |
11th Mar 2022 9:00 am |
RNS |
Update on Status under HFCAA |
9th Mar 2022 8:30 am |
RNS |
Vesting of awards under Long Term Incentive Plan |
7th Mar 2022 7:00 am |
RNS |
HUTCHMED Receives $15m Milestone from AstraZeneca |
3rd Mar 2022 3:30 pm |
RNS |
Publication of Form 20-F |
3rd Mar 2022 12:30 pm |
RNS |
Retirement of CEO and appointment of new CEO |